Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers-Reference-Cited by-同舟云学术

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Published:2019-09 Issue:9 Volume:25 Page:1415-1421
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Parikh Aparna R.,Leshchiner Ignaty^ORCID,Elagina Liudmila,Goyal Lipika,Levovitz Chaya,Siravegna Giulia,Livitz Dimitri^ORCID,Rhrissorrakrai Kahn,Martin Elizabeth E.,Van Seventer Emily E.,Hanna Megan,Slowik Kara,Utro Filippo^ORCID,Pinto Christopher J.,Wong Alicia,Danysh Brian P.,de la Cruz Ferran Fece^ORCID,Fetter Isobel J.,Nadres Brandon^ORCID,Shahzade Heather A.,Allen Jill N.,Blaszkowsky Lawrence S.,Clark Jeffrey W.,Giantonio Bruce,Murphy Janet E.,Nipp Ryan D.,Roeland Eric,Ryan David P.,Weekes Colin D.,Kwak Eunice L.,Faris Jason E.,Wo Jennifer Y.,Aguet François^ORCID,Dey-Guha Ipsita,Hazar-Rethinam Mehlika,Dias-Santagata Dora,Ting David T.^ORCID,Zhu Andrew X.,Hong Theodore S.,Golub Todd R.^ORCID,Iafrate A. John,Adalsteinsson Viktor A.,Bardelli Alberto,Parida Laxmi^ORCID,Juric Dejan^ORCID,Getz Gad^ORCID,Corcoran Ryan B.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-019-0561-9.pdf

Reference47 articles.

1. Burrell, R. A. & Swanton, C. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol. Oncol. 8, 1095–1111 (2014).

2. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).

3. McGranahan, N. & Swanton, C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 27, 15–26 (2015).

4. Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014).

5. Goyal, L. et al. Polyclonal secondary mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 7, 252–263 (2017).

Cited by 335 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic and non‐genetic drug resistance: Darwin or Lamarck?;Molecular Oncology;2024-02-02

2. Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer;Cancer Letters;2024-02

3. Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma;JAMA Network Open;2024-01-23

4. Tumor-derived cell-free DNA and circulating tumor cells: partners or rivals in metastasis formation?;Clinical and Experimental Medicine;2024-01-17

5. Circulating Tumor DNA in the Immediate Postoperative Setting;Annals of Surgical Oncology;2024-01-08